Litigation, liability and off-label risk on the balance sheet

These aren't rounding errors. They shape reported earnings, cash flow and even how you should read a "clean" balance sheet.

The accounting mechanics: reserves and contingent liabilities

Two concepts do the heavy lifting.

Litigation reserve: money a company sets aside on its balance sheet because it expects to pay out on a legal claim. Under US GAAP (Generally Accepted Accounting Principles), a company must book a reserve when a loss is *probable* and the amount is *reasonably estimable* (this is the standard under ASC 450). Under IFRS (International Financial Reporting Standards, used across Europe), the equivalent rule is IAS 37, which uses a similar "probable outflow, reliable estimate" test.

Contingent liability: a potential obligation that depends on a future event, like a court ruling. If a loss is only "reasonably possible" rather than probable, companies don't book a reserve. They disclose it in footnotes instead, often in vague language ("we believe we have meritorious defenses").

This creates a real gap between disclosed risk and recognized risk. A company can face $10 billion in claims and report a reserve of $500 million, because management genuinely believes (or argues) only a fraction is probable.

Worked example: Say a pharma company faces 10,000 lawsuits. Legal counsel estimates a 40% chance of losing each case on average, with an average payout of $150,000 per case if lost.

Expected liability = 10,000 × 0.40 × $150,000 = $600 million.

If management judges this "probable and estimable," they book a $600 million reserve, reducing net income by that amount in the period recorded. If instead they judge the outcome too uncertain to estimate reliably, they disclose it as a contingent liability in footnotes with no earnings hit, until a settlement or verdict forces recognition.

That single judgment call, probable versus reasonably possible, can swing reported earnings by hundreds of millions of dollars with no change in the underlying legal exposure.

Where it hits free cash flowfree cash flowFree Cash Flow is the cash a company generates from operations after funding the capital expenditures needed to maintain and grow its asset base.Voir la définition complète →

Reserves are accounting entries; cash payments are what actually move free cash flowfree cash flowFree Cash Flow is the cash a company generates from operations after funding the capital expenditures needed to maintain and grow its asset base.Voir la définition complète → (FCFFCFFree Cash Flow is the cash a company generates from operations after funding the capital expenditures needed to maintain and grow its asset base.Voir la définition complète →: operating cash flow minus capital expenditures).

Watch for the lag. A company might book a $2 billion reserve in Q1 but pay it out over five years as part of a structured settlement. That means:

• Net income takes the hit upfront (or in the quarter management decides to recognize it).
• Cash flow statements show the drain later, often buried in "other operating activities" or listed separately as "legal settlement payments."

Purdue Pharma's opioid settlement, structured through Chapter 11 bankruptcy, involved payments stretched over roughly a decade, into a trust for claimants. This is common: settlements get structured as annuities, not lump sums, partly to manage the paying company's cash flow.

Due diligence check: when analyzing a pharma company, always reconcile the reserve booked in a given year against the actual cash paid in that year (found in the cash flow statement or 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →/20-F footnotes). A growing gap between the two tells you whether litigation costs are front-loaded or still coming.

The insurance layer, and why it doesn't fully protect you

Product liability insurance is supposed to cushion these blows, but coverage has real limits in pharma:

• Exclusions: Many policies exclude claims tied to fraud, willful misconduct or regulatory violations, exactly the categories opioid and off-label cases often fall into.
• Coverage caps: A company might carry $500 million in product liability coverage against a $5 billion claim pool.
• Insurer disputes: Insurers frequently litigate against the pharma company itself over whether a claim is covered, adding years of uncertainty.

This is why large pharma companies self-insure a meaningful chunk of this risk through reserves rather than relying purely on external insurers. When you see "insurance recoveries" as a line item in a 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète →, check whether it's realized cash or merely an assumed future recovery still being contested.

Regulatory bodies and legal frameworks to know

To read litigation risk fluently, know the institutional landscape:

• FDA (US Food and Drug Administration): approves drugs and devices, oversees labeling, and can refer off-label marketing violations to the Department of Justice.
• DOJ (US Department of Justice): prosecutes False Claims Act cases, often the source of nine- and ten-figure settlements for off-label promotion or kickback schemes.
• EMA (European Medicines Agency): the EU-wide counterpart to the FDA for approvals; enforcement of marketing rules in Europe happens mostly at the member-state level (e.g., national health ministries and competition authorities), which fragments litigation risk compared to the US's more centralized mass-tort system.
• US Bankruptcy Courts: increasingly central to pharma litigation strategy. Purdue Pharma and J&J's talc subsidiary both attempted Chapter 11 reorganization to consolidate and cap claims, a controversial tactic sometimes called the "Texas Two-Step" (splitting a company to isolate liabilities in a subsidiary that then files for bankruptcy).

Europe generally sees fewer mass-tort-style payouts than the US, partly because of different civil procedure rules (no equivalent to US-style punitive damages or contingency-fee class actions in most EU jurisdictions), and partly because of stricter caps in some national tort systems. This is a genuine structural reason US-listed pharma companies carry higher headline litigation exposure than European peers, not just a reporting artifact.

For primary source detail on how these reserves get disclosed, the SEC's EDGAR database lets you read the actual footnote language companies use in 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète → filings, useful for comparing how conservatively different companies word similar risks.

🎬 [VIDEO: "Johnson & Johnson's Talc Bankruptcy Strategy Explained" - https://www.youtube.com/results?search_query=johnson+and+johnson+talc+bankruptcy+explained - search for recent explainer coverage of the "Texas Two-Step" bankruptcy tactic and how courts have responded to it]

Practical due-diligence checklist

When assessing a pharma company's litigation exposure:

1. Read the contingency footnote in the 10-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.Voir la définition complète → (US) or annual report (Europe) line by line; compare language year over year for softening or hardening tone.

2. Track the reserve-to-cash-paid ratio over 3-5 years to spot front-loading or deferral.

3. Check insurance coverage limits against total claim estimates disclosed by plaintiffs' attorneys or court filings.

4. Watch for bankruptcy subsidiary structures (a red flag for aggressive liability isolation, and a source of years-long uncertainty for creditors and investors alike).

5. Compare US versus ex-US exposure: a company with concentrated US sales carries structurally higher mass-tort risk than one diversified into Europe and Asia.

Key Takeaways

• Litigation reserves and contingent liabilities are governed by distinct accounting thresholds (ASC 450 in the US, IAS 37 under IFRS): "probable and estimable" gets a reserve; "reasonably possible" gets a footnote only, no earnings hit.
• Reported earnings and actual cash flow diverge on litigation: reserves hit net income immediately, but cash payments are often stretched over years through structured settlements.
• Product liability insurance covers less than headline coverage limits suggest, due to exclusions for regulatory violations and willful misconduct, exactly where opioid and off-label cases usually land.
• The US mass-tort and bankruptcy system (including tactics like subsidiary-isolation bankruptcy) creates materially higher litigation exposure for US-concentrated pharma companies than for peers weighted toward Europe.
• Always reconcile disclosed reserves against actual cash paid over multiple years. That gap is where the real risk hides.